November 20th 2024
The TROPION-Lung12 trial uses a circulating tumor DNA assay to preoperatively screen patients with non–small cell lung cancer for eligibility in post-surgical adjuvant treatment regimens.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Immunotherapy Combinations Provide Long-Term Benefit in Stage IV NSCLC
June 17th 2020In an interview with Targeted Oncology, Suresh Ramalingam, MD, FASCO, discussed the findings from the CheckMate 227 study that support the FDA’s approval of the combination of nivolumab and ipilimumab in patients with advanced NSCLC.
Read More
RET Inhibition Shows Significant Intracranial Responses in RET-Altered NSCLC
June 5th 2020"Selpercatinib had marked intracranial anti-tumor activity in RET fusion–positive patients with [NSCLC and] CNS metastases. Tumor responses were durable, independently confirmed, and observed in patients with prior systemic chemotherapy."
Read More
Pralsetinib Demonstrates Significant Findings in RET+ Solid Tumors as FDA Grants Priority Review
June 1st 2020"The ARROW trial results presented today during the ASCO virtual meeting showed that patients with RET fusion–positive lung cancer treated with the selective RET inhibitor pralsetinib had durable responses. In addition to supporting the development of pralsetinib across a broad population, these data highlight the urgency to test [patients with] lung cancer with next-generation sequencing so that eligible patients may be identified for treatment."
Read More
Updated Data Displays Better OS With Use of Alectinib Over Crizotinib in ALK+ NSCLC
May 31st 2020Patients with ALK-positive non–small cell lung cancer showed clinically meaningful improvement in overall survival when receiving alectinib, a highly selective second-generation TKI, versus those treated with crizotinib, according to updated data from the pivotal phase 3 ALEX trial presented at the 2020 ASCO Virtual Scientific Program.
Read More
Investigation of Tepotinib Shows Durable Benefit in NSCLC With a METex14 Skipping Mutation
May 31st 2020Durable clinical activity was demonstrated with tepotinib, an oral, highly selective MET inhibitor, in patients with locally advanced or metastatic non–small cell lung cancer and a MET exon 14 skipping mutation identified through liquid or tissue biopsy. This data was from the phase 2 VISION trial presented during the at the 2020 Virtual Scientific Meeting and published in the New England Journal of Medicine.
Read More
Patients With No Prior Therapy for Advanced Squamous NSCLC Respond to Tislelizumab Combo
May 30th 2020Phase 3 BGB-A317-307 trial results showed statistically significant improvements in progression-free survival with tislelizumab plus chemotherapy versus chemotherapy alone in Chinese patients with untreated advanced squamous non–small cell lung cancer.
Read More
CASPIAN Update Shows Ongoing Survival Benefit With Durvalumab in ES-SCLC
May 30th 2020“Importantly, the separation among the curves seems to be observed over time and, indeed, survival at 2 years improves from 14% [of participants] in the control arm to 22% on the experimental arm. The magnitude of the benefit is very similar and very consistent across all the prespecified subgroups of patients analyzed, including those treated with cisplatin or those patients with liver or brain metastases.”
Read More
OS Benefit Observed With Frontline Nivolumab/Ipilimumab Plus Limited Chemotherapy in NSCLC
May 29th 2020"CheckMate 9LA met its primary end point of overall survival at the pre-planned interim analysis…With early separation of overall survival curves and lower progressive disease rates as best overall response, the hypothesis for this study design was validated."
Read More
Modest survival benefits were observed in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum compared with patients who received EP and placebo. Although progression-free survival rates reached the threshold for significance, overall survival rates failed to reach the prespecified threshold, according to data from the phase 3 KEYNOTE-604 trial.
Read More
Durable Responses Elicited with Nivolumab Plus Ipilimumab in Advanced NSCLC
May 29th 2020"Based on these results, we note that the combination of nivolumab and ipilimumab, which is now approved by the United States FDA, is a novel chemotherapy-sparing first-line treatment approach for advanced-stage non-small-cell lung cancer."
Read More
Co-Inhibition of TIGIT and PD-L1 Generates Promising Efficacy in NSCLC
May 29th 2020Frontline treatment with the TIGIT inhibitor tiragolumab plus atezolizumab demonstrated greater efficacy versus single-agent checkpoint inhibitor therapy in locally advanced or metastatic non–small cell lung cancer, according to results of the phase 2 CITYSCAPE trial reported at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
Read More